TORONTO, Dec. 6, 2022 /CNW/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CNSX:MEND.CN) (Frankfurt: 8TV) (OTC:MNNDF), a company focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions developed by NetraMark (a wholly owned subsidiary of the Company) announces that Dr. Joseph Geraci, Nurosene's Chief Science Officer, will be participating in the Advancing Drug Development Forum on December 14th, 2022 in Boston, MA.
Read more at newswire.caNUROSENE CHIEF SCIENCE OFFICER PRESENTS AT LEADING DRUG DEVELOPMENT FORUM
Newswire.ca - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Technology%20abstract%20by%20TU%20IS%20via%20iStock.jpg)
/Quantum%20Computing/A%20concept%20image%20with%20a%20brain%20on%20top%20of%20a%20blue%20circuit%20board_%20Image%20by%20Gorodenkoff%20via%20Shutterstock_.jpg)